The Short Answer
Crohn's disease can go into remission (no active inflammation) with early treatment using TNF-α inhibitors (infliximab, adalimumab) or newer biologic drugs. About 60–70% of patients achieve remission within 8 weeks of starting therapy [7]. However, Crohn's is a chronic condition—remission requires ongoing maintenance therapy, and flares can recur if you stop treatment [7].
Crohn's disease causes deep ulcers and inflammation in the small intestine (especially the ileum, the last section before the colon). Without treatment, repeated inflammation leads to scarring, strictures (narrowing), and fistulas (abnormal tunnels between bowel loops) [7]. Early aggressive therapy with TNF-α inhibitors stops this progression [7].
TNF-α inhibitors (infliximab 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks) work by blocking tumor necrosis factor, a key inflammatory chemical. Clinical remission (no symptoms, normal labs) occurs in 60–70% of patients by week 8 [7]. Newer biologics (vedolizumab, ustekinumab) work differently and are options if TNF inhibitors fail [7].
Maintenance therapy is lifelong. If you stop TNF inhibitors, flare rates jump to 50–70% within 6 months [7]. Costs are high ($1,500–$2,500/month), but biosimilars and insurance copay assistance programs reduce out-of-pocket costs to $0–$250/month [7].